ProQR Therapeutics (PRQR) Research & Development (2012 - 2026)

ProQR Therapeutics has reported Research & Development for 15 years, with the latest figure at $13.8 million in Q1 2026.

• Quarterly Research & Development rose 6.85% year-over-year to $13.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.6 million (up 31.24% YoY) and the FY2025 annual result came in at $52.1 million, up 34.03% from the prior year.
• Research & Development eased to $13.8 million in Q1 2026 per PRQR's latest filing, from $92.6 million in the prior quarter.
• Over five years, Research & Development peaked at $92.9 million in Q4 2022 and troughed at -$15.5 million in Q3 2022.
• A 5-year average of $12.3 million and a median of -$6.5 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development jumped 751.81% in 2022, then sank 74.39% in 2024.
• Over 5 years, Research & Development stood at $92.9 million in 2022, then sank by 50.69% to $45.8 million in 2023, then surged by 44.91% to $66.4 million in 2024, then jumped by 39.53% to $92.6 million in 2025, then tumbled by 85.04% to $13.8 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $13.8 million, $92.6 million, and -$13.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.